Royal Bank of Canada’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-100,694
| Closed | -$17.3M | – | 8259 |
|
|
2021
Q3 | $17.3M | Buy |
100,694
+25,684
| +34% | +$3.36M | ﹤0.01% | 1449 |
|
|
2021
Q2 | $9.41M | Sell |
75,010
-457
| -0.6% | -$57.6K | ﹤0.01% | 1850 |
|
|
2021
Q1 | $10.2M | Sell |
75,467
-1,785
| -2% | -$231K | ﹤0.01% | 1751 |
|
|
2020
Q4 | $9.88M | Buy |
77,252
+7,196
| +10% | +$844K | ﹤0.01% | 1721 |
|
|
2020
Q3 | $7.88M | Buy |
70,056
+26,721
| +62% | +$2.66M | ﹤0.01% | 1699 |
|
|
2020
Q2 | $4.13M | Buy |
43,335
+42,502
| +5,102% | +$4.1M | ﹤0.01% | 2079 |
|
|
2020
Q1 | $75K | Sell |
833
-2,014
| -71% | -$157K | ﹤0.01% | 4944 |
|
|
2019
Q4 | $151K | Buy |
2,847
+2,760
| +3,172% | +$126K | ﹤0.01% | 4820 |
|
|
2019
Q3 | $3K | Sell |
87
-109
| -56% | -$4.73K | ﹤0.01% | 6243 |
|
|
2019
Q2 | $8K | Buy |
196
+76
| +63% | +$3.15K | ﹤0.01% | 6143 |
|
|
2019
Q1 | $6K | Sell |
120
-37
| -24% | -$1.63K | ﹤0.01% | 6233 |
|
|
2018
Q4 | $7K | Sell |
157
-840
| -84% | -$42K | ﹤0.01% | 6070 |
|
|
2018
Q3 | $57K | Buy |
997
+736
| +282% | +$36.2K | ﹤0.01% | 5175 |
|
|
2018
Q2 | $13K | Buy |
261
+229
| +716% | +$8.34K | ﹤0.01% | 5748 |
|
|
2018
Q1 | $2K | Sell |
32
-284
| -90% | -$12.1K | ﹤0.01% | 6150 |
|
|
2017
Q4 | $14K | Sell |
316
-2,763
| -90% | -$104K | ﹤0.01% | 5751 |
|
|
2017
Q3 | $115K | Buy |
3,079
+2,990
| +3,360% | +$104K | ﹤0.01% | 4915 |
|
|
2017
Q2 | $3K | Sell |
89
-899
| -91% | -$26.1K | ﹤0.01% | 6214 |
|
|
2017
Q1 | $26K | Sell |
988
-623
| -39% | -$16.4K | ﹤0.01% | 5497 |
|
|
2016
Q4 | $41K | Buy |
1,611
+1,538
| +2,107% | +$48.7K | ﹤0.01% | 5376 |
|
|
2016
Q3 | $3K | Buy |
73
+21
| +40% | +$696 | ﹤0.01% | 6122 |
|
|
2016
Q2 | $2K | Hold |
52
| – | – | ﹤0.01% | 6178 |
|
|
2016
Q1 | $1K | Buy |
52
+19
| +58% | +$553 | ﹤0.01% | 6259 |
|
|
2015
Q4 | $2K | Sell |
33
-1,008
| -97% | -$36.3K | ﹤0.01% | 6401 |
|
|
2015
Q3 | $26K | Sell |
1,041
-365
| -26% | -$11K | ﹤0.01% | 5463 |
|
|
2015
Q2 | $44K | Buy |
1,406
+1,281
| +1,025% | +$41.3K | ﹤0.01% | 5291 |
|
|
2015
Q1 | $5K | Sell |
125
-69
| -36% | -$2.74K | ﹤0.01% | 5753 |
|
|
2014
Q4 | $8K | Buy |
+194
| New | +$6.76K | ﹤0.01% | 5683 |
|
Royal Bank of Canada's XLRN Position: Q4 2021 in Review
Royal Bank of Canada sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 100,694 shares — an estimated $17.3M sold.
Royal Bank of Canada first reported a position in XLRN in Q4 2014 and held it in 28 quarters. The position peaked at $17.3M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Royal Bank of Canada reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Royal Bank of Canada sold 100,694 Acceleron Pharma shares in Q4 2021, an estimated $17.3M.
- Royal Bank of Canada first reported a position in Acceleron Pharma in Q4 2014 and held it in 28 quarters.
- Royal Bank of Canada's Acceleron Pharma position peaked at $17.3M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Royal Bank of Canada's 13F filing for Q4 2021, filed 14 Feb 2022.